Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients.

Carlos Gustavo Wambier Thaís Angélica Hoekstra Sarah Perillo de Farias Wambier Roberto Bueno Filho Fernando Crivelenti Vilar Renato Soriani Paschoal Ana Maria Roselino Marco Andrey Cipriani Frade Norma Tiraboschi Foss

Published in: Anais brasileiros de dermatologia (2019)

SCORTEN is valid for the Brazilian population, including among those patients with acquired immunodeficiency syndrome, and, as such, its use is recommended for aiding treatment choice in this subgroup of patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
clinical trial
patient reported outcomes
antiretroviral therapy
study protocol
open label
replacement therapy
combination therapy
wound healing